GRI Bio, Inc. — Form 8-K Summary
Business Context and Reporting Period
This Form 8-K, filed February 2, 2024, reports financing agreements entered into on February 1, 2024. GRI Bio is a Nasdaq-listed emerging growth company focused on biotechnology. The filing is event-based and does not provide quarterly or annual operating results.
Financing and Key Financial Terms
- The company agreed to sell 330,450 common shares and 4,669,550 pre-funded warrants exercisable for an equal number of common shares.
- The offering also includes 5,000,000 Series B-1 common warrants and 5,000,000 Series B-2 common warrants.
- Securities are sold in units consisting of one share or pre-funded warrant, one Series B-1 warrant, and one Series B-2 warrant, at a purchase price of $1.10 per unit. The price is reduced by $0.0001 for each pre-funded warrant.
- The stated pricing implies approximately $5.5 million of gross proceeds before placement-agent fees and other offering expenses, subject to the offering closing and final terms.
- Each pre-funded warrant is exercisable for one common share at $0.0001 per share, does not expire, and is subject to ownership limitations.
- Each Series B-1 warrant is exercisable at $1.10 per share for five years after issuance. Each Series B-2 warrant is exercisable at $1.10 per share for 18 months after issuance.
- If all warrants are exercised, the securities could result in up to 14,669,550 additional common shares, comprising 4,669,550 pre-funded warrant shares and 10,000,000 common warrant shares, subject to adjustments and ownership limitations.
- The offering was expected to close on February 6, 2024. The filing does not confirm the actual closing, net proceeds, cash balance, liquidity runway, revenue, profit, cash flow, margins, or debt.
Material Changes, Costs, and Other Terms
- GRI Bio entered into a placement agency agreement with A.G.P./Alliance Global Partners, which will act as exclusive placement agent.
- A.G.P. will receive a cash fee equal to 7.0% of gross offering proceeds, reimbursement of accountable legal expenses up to $100,000, and a non-accountable expense allowance of up to $25,000.
- The company’s executive officers and directors agreed to 90-day lock-up restrictions following the offering’s closing, subject to specified exceptions and A.G.P.’s consent.
- The offering is being conducted under the company’s Form S-1 registration statement, Registration No. 333-276205.
Guidance, Outlook, Risks, and Unusual Items
- The filing does not provide operating guidance, clinical or regulatory milestones, revenue expectations, or management commentary on the use of proceeds.
- The financing creates potential dilution from the shares, pre-funded warrants, and common warrants.
- Exercise of the common warrants is dependent on the stock price, warrant terms, ownership limitations, and the availability of an effective registration or applicable exercise mechanism.
- The offering remained subject to closing conditions as of the filing. The filing text does not state whether the offering ultimately closed or the amount of net proceeds received.
- Investors should review the complete warrant, purchase agreement, placement agency agreement, lock-up agreement, and February 2, 2024 press release filed as exhibits.
Facts Investors Should Verify
- Whether the offering closed on February 6, 2024 and the final gross and net proceeds received.
- The company’s post-offering cash balance and expected liquidity runway.
- The number of common shares outstanding after issuance and the potential fully diluted share count.
- The detailed anti-dilution, adjustment, exercise, and ownership-limitation provisions in the warrant agreements.
- The intended use of proceeds and any subsequent operating, clinical, financing, or regulatory developments.